Experts hesitate on weight loss ETFs amid the obesity drug boom
While weight loss drugmakers are catching a bid with investors, experts are less certain that ETFs linked to the category can achieve the same success.
Source link
- OpenAI’s deals with publishers could spell trouble for rivals | TechCrunch
- Chinese stocks are ‘a risk worth taking,’ asset manager says — naming 2 he likes
